Darolutamide 联合 ADT 与 ADT 治疗转移性激素敏感性前列腺癌 (ARANOTE)
转移性激素敏感性前列腺癌 (mHSPC) 患者中 Darolutamide 联合雄激素剥夺疗法 (ADT) 对比安慰剂加 ADT 的随机、双盲、安慰剂对照 3 期研究
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Beijing、中国、100083
- Peking University Third Hospital
-
Beijing、中国、100000
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Anhui
-
Hefei City, Anhui Province、Anhui、中国、230031
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- Beijing Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- Sun Yat-sen University Cancer Center
-
Guangzhou、Guangdong、中国、510180
- Guangzhou First People Hospital
-
Shenzhen、Guangdong、中国、518172
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
Wuhan、Hubei、中国、430079
- Hubei Cancer Hospital
-
Wuhan、Hubei、中国、430071
- Zhongnan hospital ,Wuhan University
-
-
Hunan
-
Changsha、Hunan、中国、410013
- Hunan Cancer Hospital - Oncology Department
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
-
Nantong、Jiangsu、中国、226361
- Nantong tumor hospital
-
Suzhou、Jiangsu、中国、215004
- The 2nd Affiliated Hospital of Soochow University
-
-
Jilin
-
Changchun、Jilin、中国、130021
- 1st Hospital of Jilin University
-
-
Liaoning
-
Shengyang、Liaoning、中国、110042
- Liaoning Cancer Hospital and Institute
-
-
Shandong
-
Yantai、Shandong、中国、264000
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Xi’an、Shanxi、中国、710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
-
Chengdu、Sichuan、中国、MISSING
- Sichuan University West China Hospital
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310000
- The 1st Affiliated Hospital of Zhejiang University
-
Hangzhou、Zhejiang、中国、310014
- ZheJiang Provincial People's Hospital
-
Ningbo、Zhejiang、中国、315010
- Ningbo First Hospital
-
Wenzhou、Zhejiang、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Cherkasy、乌克兰、18009
- CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
-
Dnipro、乌克兰、49102
- City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
-
Kyiv、乌克兰、4107
- Kyiv Regional Oncological Dispensary
-
Kyiv、乌克兰、02660
- Kyiv City Hospital #3 - Department of Urology
-
-
-
-
-
Arkhangelsk、俄罗斯、163045
- Arkhangelsk Clinical Oncology Dispensary
-
Chelyabinsk、俄罗斯、454087
- Chelyabinsk Regional Oncology Dispensary
-
Chelyabinsk、俄罗斯、454048
- Ltd "EVIMED"
-
Ivanovo、俄罗斯、153040
- Ivanovo Regional Oncology Dispensary
-
Kazan'、俄罗斯、420029
- Republican Clinical Oncology Dispensary Kazan
-
Moscow、俄罗斯、117997
- Research Centre of X-ray and Radiology
-
Nizhny Novgorod、俄罗斯、603109
- Volga District Med Center FMBA
-
Novosibirsk、俄罗斯、630099
- LLC Reafan
-
Novosibirsk、俄罗斯、630099
- Medical Center "Avicenna"
-
Omsk、俄罗斯、644013
- Clinical Oncological Dispensary of Omsk Region
-
Saint Petersburg、俄罗斯、196006
- AV Medical Group
-
Saint Petersburg、俄罗斯、197758
- Russian Scientific Radiology and Surgery Technologies Center
-
Saint Petersburg、俄罗斯、197758
- Scientific Research Instutute of Oncology n.a. N.N. Petrov
-
Tyumen、俄罗斯、625041
- Multi-Field Clinical Medical Center "Medical City"
-
Ufa、俄罗斯、450054
- Republican Clinical Oncology Dispensary
-
Vologda、俄罗斯、160022
- Vologda Regional Hospital
-
Yekaterinburg、俄罗斯、620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
Ontario
-
Burlington、Ontario、加拿大、L7N 3V2
- G. Kenneth Jansz Medicine Professional Corporation
-
-
Quebec
-
Montreal、Quebec、加拿大、H2X 0A9
- Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
-
-
-
-
-
Cape Town、南非、7570
- Cape Town Oncology Trials
-
-
Eastern Cape
-
Port Elizabeth、Eastern Cape、南非、6045
- Cancercare Langenhoven
-
-
Gauteng
-
Johannesburg、Gauteng、南非、1475
- East Rand Medical Research Unit
-
Pretoria、Gauteng、南非、2
- University of Pretoria, Clinical Research Unit
-
-
-
-
-
Chandigarh、印度、160012
- Post Graduate Institute of Medical Education and Research
-
Kolkata、印度、700156
- Tata Medical Center
-
Nashik、印度、422009
- Apex Wellness Hospital
-
New Delhi、印度、110 085
- Rajiv Gandhi Cancer Institute & Research Centre
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、印度、530017
- Mahatma Gandhi Cancer Hospital & Research Institute
-
-
Gujarat
-
Ahmedabad、Gujarat、印度、380016
- The Gujarat Cancer & Research Institute
-
Ahmedabad、Gujarat、印度、380060
- HCG Cancer Centre - Ahmedabad
-
Vadodara、Gujarat、印度、390007
- Cancer Care Clinic - Vadodara
-
-
Karnataka
-
Belagavi、Karnataka、印度、590010
- K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
-
Bengaluru、Karnataka、印度、560027
- Healthcare Global Enterprises Ltd
-
-
Kerala
-
Kochi、Kerala、印度、682 041
- Amrita Institute of Medical Sciences
-
Thiruvananthapuram、Kerala、印度、695011
- Regional Cancer Centre - Thiruvananthapuram
-
-
Maharashtra
-
Chhatrapati Sambhajinagar、Maharashtra、印度、431001
- Marathwada Regional Cancer Centre and Research Institute
-
Mumbai、Maharashtra、印度、400026
- Jaslok Hospital and Research Centre
-
Nashik、Maharashtra、印度、422004
- Curie Manavata Cancer Centre
-
Pune、Maharashtra、印度、411001
- Jehangir Hospital
-
-
Odisha
-
Bhubaneswar、Odisha、印度、751019
- All India Institute of Medical Sciences
-
Bhubaneswar、Odisha、印度、751007
- Sparsh Hospital & Critical Care
-
-
Puducherry
-
Gorimedu、Puducherry、印度、605006
- Jawaharlal Institute Of Postgraduate Medical Education and R
-
-
Punjab
-
Ludhiana、Punjab、印度、141008
- Christian Medical Center & Hospital
-
-
Rajasthan
-
Jaipur、Rajasthan、印度、302017
- Sawami Man Singh (SMS) Medical College & Attached Hospitals
-
-
Tamil Nadu
-
Madurai、Tamil Nadu、印度、625020
- Apollo Speciality Hospitals
-
Madurai、Tamil Nadu、印度、625107
- Meenakshi Mission Hospital & Research Centre
-
-
-
-
-
Changhua、台湾、50006
- Changhua Christian Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
Kaohsiung
-
Kaohsiung City、Kaohsiung、台湾、807377
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
-
-
-
Rio de Janeiro、巴西、22793-080
- Instituto COI de Educação e Pesquisa
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、41950-640
- Assistência Multidisciplinar em Oncologia (AMO)
-
-
Goiás
-
Goiânia、Goiás、巴西、74605-070
- Hosp. Araujo Jorge da Associação de Combate ao Câncer
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、30130-100
- Hospital da Universidade Federal de Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、30150-270
- Cetus Oncologia Hospital Dia
-
-
Paraná
-
Curitiba、Paraná、巴西、81520-060
- Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、巴西、59040-000
- Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
-
-
Rio Grande do Sul
-
Pelotas、Rio Grande do Sul、巴西、96020-080
- Unidade de Pesquisas Clinicas em Oncologia
-
Porto Alegre、Rio Grande do Sul、巴西、90850-170
- Hospital Mae de Deus
-
Porto Alegre、Rio Grande do Sul、巴西、91350-280
- FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
-
Porto Alegre、Rio Grande do Sul、巴西、90020-090
- Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
-
-
São Paulo
-
Barretos/SP、São Paulo、巴西、14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
São José do Rio Preto、São Paulo、巴西、15090-000
- Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
-
São Paulo、São Paulo、巴西、03102-002
- IBCC - Instituto Brasileiro de Controle do Cancer
-
São Paulo、São Paulo、巴西、01243-020
- Urobrasil
-
São Paulo、São Paulo、巴西、04039-004
- Inst. de Assistência Médica ao Sérvidor Público Estadual
-
-
-
-
-
Daugavpils、拉脱维亚、LV-5417
- Daugavpils Regional Hospital
-
Riga、拉脱维亚、1038
- RAKUS Hospital Gailezers
-
Riga、拉脱维亚、LV-1001
- URO Ltd.
-
Riga、拉脱维亚、LV-1002
- P. Stradins Clinical University Hospital
-
Valmiera、拉脱维亚、LV-4201
- Vidzemes Hospital
-
-
-
-
Bay of Plenty
-
Tauranga、Bay of Plenty、新西兰、3112
- Tauranga Urology Research Limited
-
-
Canterbury
-
Christchurch、Canterbury、新西兰、8013
- Canterbury Urology Research Trust
-
-
Waikato Region
-
Hamilton、Waikato Region、新西兰、3240
- Waikato Hospital
-
-
-
-
-
Santiago、智利、7510032
- Oncovida
-
Santiago、智利
- UROMED
-
Santiago、智利、TBC
- Hospital Clínico de la Pontificia Univ. Católica de Chile
-
Santiago、智利、7500921
- Fundación Arturo López Perez
-
-
Araucania
-
Temuco、Araucania、智利、4781156
- Centro de Investigación Clínica del Sur
-
-
Santiago Metropolitan
-
Providencia、Santiago Metropolitan、智利、7500653
- Centro de Estudios Clínicos SAGA SpA
-
-
Valparaiso
-
Viña del Mar、Valparaiso、智利、2520598
- OncoCentro
-
-
-
-
New South Wales
-
Kingswood、New South Wales、澳大利亚、2747
- Nepean Hospital
-
St Leonards、New South Wales、澳大利亚、2065
- Northern Cancer Institute
-
Sydney、New South Wales、澳大利亚、2109
- Macquarie University Hospital - Oncology Department
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Cancer Research South Australia
-
-
Victoria
-
Frankston、Victoria、澳大利亚、3199
- Peninsula Oncology Centre
-
Heidelberg、Victoria、澳大利亚、3084
- Austin Health
-
-
-
-
-
Lima、秘鲁、LIMA 11
- Hospital Militar Luis Arias Schreiber
-
Lima、秘鲁、LIMA 27
- Clínica El Golf
-
-
Lima region
-
San Isidro、Lima region、秘鲁、15036
- Aliada
-
Santiago de Surco、Lima region、秘鲁、15033
- Hospital Guillermo Almenara Irigoyen
-
-
-
-
-
Kaunas、立陶宛、LT-50009
- The Hospital of Lithuanian University of Health SciencesLUHS
-
Klaipėda、立陶宛、LT-92288
- PI Klaipedos University Hospital
-
Vilnius、立陶宛、LT-08660
- National Cancer Institute
-
Vilnius、立陶宛、LT-08661
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Barcelona、西班牙、08025
- Fundacio Puigvert | Urologia
-
Barcelona、西班牙、08208
- Parc Tauli Hospital Universitari | Oncologia
-
Cáceres、西班牙、10003
- Hospital San Pedro De Alcantara | Oncologia
-
Málaga、西班牙、20910
- Hospital Universitario Virgen De La Victoria | Urologia
-
Seville、西班牙、41013
- Hospital Universitario Virgen Del Rocio S.L. | Urologia
-
-
Madrid
-
Alcorcón、Madrid、西班牙、28922
- Hospital Universitario Fundacion Alcorcon | Urologia
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of prostate
- Metastatic disease
- Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
- Treatment with radiotherapy within 2 weeks before randomization
- Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
- Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
- Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
- A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
- Inability to swallow oral medications
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Darolutamide+ADT
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy |
Coated tablet, oral administration Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy |
|
安慰剂比较:Placebo+ADT
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy |
Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy Coated tablet matching Darolutamide in appearance, oral administration |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Radiological Progression-free Survival (rPFS) Assessed by Central Review
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:From randomization to the final analysis date, approximately 47 months
|
Time from the date of randomization to the date of death from any cause. |
From randomization to the final analysis date, approximately 47 months
|
|
Time to Castration-Resistant Prostate Cancer (CRPC)
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first). |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Initiation of Subsequent Anti-cancer Therapy
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to PSA Progression
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
PSA Undetectable Rates (<0.2 ng/mL)
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Pain Progression
大体时间:From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Number of Participants With Adverse Events as a Measure of Safety
大体时间:From start of study drug administration until 30 days after the last administration
|
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug. |
From start of study drug administration until 30 days after the last administration
|
合作者和调查者
出版物和有用的链接
一般刊物
- Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16.
- Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.07.026. Online ahead of print.
- Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 May;27(5):614-624. doi: 10.1016/S1470-2045(26)00014-8. Epub 2026 Apr 9.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 21140
- 2020-003093-48 (EudraCT编号)
- 2022-502244-12-00 (其他标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.